ABL1 and leukemia: Overexpression of BCR-ABL and P-glycoprotein (Pgp) is a known mechanism underlying imatinib resistance, and NHE1 is an important target that has been implicated in the reversal of imatinib resistance in resistant leukaemia (K562) cell lines and in BCR-ABL-positive patient cells [68].